Virtual Library

Start Your Search

Cécilia Nocent



Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-05 - EGFR-2013-CPHG, a Real-World Study of EGFR Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with Erlotinib (ID 892)

      08:00 - 18:00  |  Author(s): Cécilia Nocent

      • Abstract
      • Slides

      Background

      Erlotinib (E) is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor labelled in France and effective as a first-line treatment in advanced non-small-cell lung cancer (NSCLC). E has demonstrated a better efficacy than chemotherapy in EGFR mutant NSCLC in phase III trials.

      Method

      We undertook a multicentric study in 42 French Nonacademic Hospital Centres. Patients aged 18 years and older with histologically confirmed stage IIIB or IV NSCLC and harboring a confirmed activating mutation of EGFR received oral E (150 mg/day). We report here patient characteristics, progression-free survival (PFS), overall survival (OS), and safety data. Statistical analyses by R software were based on a Cox model and Kaplan-Meier method.

      Result

      Between April 1st, 2014 and March 31st, 2016, 184 patients were recruited: mean age = 72 years old, 125 (69.5%) female, 158 (90.8%) Caucasians, 112 (63.6%) non-smokers, 167 (94.9%) adenocarcinoma (21 stage IIIB and 156 stage IV), 127 (65.6%) ECOG 0-1, 40 (26%) brain metastasis at inclusion and 75 (42.4%) were treated by E in second- or latter line. 179 patients were included in the PFS and OS analysis. Median follow-up was 23.8 months, median PFS was 11.7 months and median OS was 25.8 months. Median survival rates at one year were 48.6% for PFS and 75% for OS. Risk of death was not correlated with brain metastasis (HR=1.15, IC95:0.67-1.97, p=0.296) but with ECOG = 2 (HR=4.55, IC95:2.05-10.10, p<0,001). E had a manageable safety profile (7.7% grade 3-4 adverse events at 6 months) and no new safety signals were identified.

      N %
      Patients 184
      Mean age (years) 72
      Sex

      Males

      Females

      59

      125

      30.5

      69.5

      Race
      Caucasians 158 90.8
      Smoking status
      Non-smokers 112 63.6
      Histological type
      Adenocarcinoma 167 94.9
      Staging

      Stade IIIB

      Stade IV

      21

      156

      ECOG
      0 or 1 127 65.7
      Brain metastases at inclusion 40 26
      Second-lind therapeutic strategy and more
      Erlotinib 75 42.4
      Progression-free survival and overall survival 179

      Median Progression-free survival (Months)

      Median Overall Survival (Months)

      11.7

      25.8

      Conclusion

      Data from EGFR-2013-CPHG real-world study are consistent with the efficacy and safety of E in EGFR mutant NSCLC patients seen in phase III clinical trials.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.